Prescription Behavior Study: Cardiology Therapy Adoption & Brand Switching Dynamics in Tier 1 Cities
A physician perception and prescription analytics study across cardiologists and general physicians in 6 metros
Study Overview
InsightRx conducted a prescription behavior study for a leading pharma company evaluating therapy adoption patterns in the cardiology segment. The research mapped how cardiologists and GPs make prescribing decisions, what drives brand switching, and how field-force engagement influences prescription behavior.
Prescription Decision Architecture
Our research mapped the full prescription decision architecture for cardiology molecules — from initial awareness through trial to habitual prescribing. The study found that the journey from awareness to first prescription averages 4.2 months for new molecules, with KOL endorsement at CMEs being the single most influential trigger (cited by 71% of cardiologists). Importantly, the research identified a 'prescription inertia' phenomenon: once a physician prescribes a molecule for 3+ consecutive patients, brand switching probability drops by 67% — making early adoption critical for new entrants.
Brand Switching Triggers & Competitive Vulnerability
We identified 6 primary brand switching triggers through our physician panel research: competitor rep visit with clinical data (38%), patient complaint about side effects (29%), price reduction by competitor (24%), formulary change at primary hospital (19%), peer recommendation at CME (17%), and digital content from competitor brand (11%). The research revealed that GPs are significantly more susceptible to switching than cardiologists — a finding that led the client to differentiate their GP and specialist engagement strategies.
Field-Force Effectiveness Assessment
Our field-force effectiveness study benchmarked the client's medical representative performance against two key competitors across 6 cities. The research found significant gaps in digital engagement capability — while 44% of cardiologists under 45 prefer digital detailing, only 12% of the client's field interactions used digital formats. The study also identified 'high-value physician clusters' — groups of 15–20 physicians in each city whose prescription behavior disproportionately influences peers — enabling a targeted engagement strategy.
Key Findings
- Brand familiarity from medical education (KOL endorsement) is the #1 prescription trigger for new molecules
- 38% of GPs switch cardiology brands within 6 months of a competitor rep visit — highest switching rate across therapy areas studied
- Patient affordability concerns influence 52% of prescription decisions in Tier 2 cities
- Generic substitution at pharmacy level affects 31% of branded cardiology prescriptions
- Digital detailing is preferred by 44% of cardiologists under 45 — but only 12% of field-force interactions use digital formats
- Hospital formulary inclusion drives 3x higher prescription volume for institutional brands
Research Approach
Methodology
- Physician panel surveys (n=480)
- Prescription analytics
- Field-force effectiveness audits
- Chemist recommendation studies
- KOL depth interviews
Coverage
6 metros — Mumbai, Delhi, Bengaluru, Chennai, Hyderabad, Kolkata
Stakeholders
Commission a similar study
Every InsightRx study is custom-designed for your specific market, geography, and research question.
Request a Briefing